Published in:
Open Access 01-09-2016 | Erratum
Erratum to: Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting
Published in: Infectious Diseases and Therapy | Issue 3/2016
Login to get accessExcerpt
Following publication of the aforementioned article, the authors noted a minor error in Table 1 and two small errors in Table 2. In Table 1, the Eron Class III Clinical Criteria should read CrCl <30 mL/min or on dialysis, not CrCl <20 mL/min. In Table 2, Distribution of SOLO patients in modified Eron Classes I–III, the number of outpatients receiving vancomycin (VAN) in Class I should be 111, not 11. The total number of inpatients (Class I–III) was omitted, n = 1143 (59.8%).
Table 1
Clinical criteria used to define modified Eron Classes I–IV
|
Eron class
|
Clinical criteria
|
|---|---|
|
IV
|
Bacteremia (positive blood culture); or
Absolute total neutrophils count <500
|
|
III
|
Meeting SIRS criteria
CrCl <30 mL/min or on dialysis
ALT/AST >10-times ULN
Heart rate >90/min, breath rate >20/min, or systolic BP <90 mmHg; or
Cancer
|
|
II
|
Age ≥75 years old
Glucose >11.1 mmol/L
Congestive heart failure at the randomization
30 mL/min < CrCl <60 mL/min
Hepatitis (excluding AST/ALT >10-times ULN)
Peripheral vascular disease
Diabetes mellitus
Fever (temperature >38.0 °C); or
BMI ≥30 kg/m2
|
|
I
|
For the patients who didn’t meet Classes II–IV
|
Table 2
Distribution of SOLO patients in modified Eron Classes I–III (mITT population, n = 1959)
|
Class I
|
Class II
|
Class III
|
Total (Class I–III)
|
|
|---|---|---|---|---|
|
SOLO mITT (n = 1959)
|
520 (26.5%)
|
790 (40.3%)
|
600 (30.6%)
|
1910
|
|
Inpatients, n (%)
|
301 (57.9%)
|
431 (54.6%)
|
411 (68.5%)
|
1143 (59.8%)
|
|
ORI, n
|
144
|
224
|
203
|
571
|
|
VAN, n
|
157
|
207
|
208
|
572
|
|
Outpatients, n (%)
|
219 (42.1%)
|
359 (45.4%)
|
189 (31.5%)
|
767 (40.2%)
|
|
ORI, n
|
108
|
182
|
89
|
379
|
|
VAN, n
|
111
|
177
|
100
|
388
|